Paolo Tarantino, Research Fellow at Dana Farber Cancer Institute shared a post by Roberto Caramagani Pestana, Clinical oncologist at Israelita Albert Einstein Hospital, on LinkedIn:

“Wonderful experience to brainstorm about the agnostic potential of Antibody Drug Conjugates with Roberto Carmagnani Pestana, in this review article, which was among the most cited of 2022-2023 on CA: A Cancer Journal for Clinicians, and which started a long-lasting friendship with Roberto.

With Transtuzumab Deruxtecan (T-DXd) now approved agnostically for patients with HER2 IHC 3+ cancers, what was only a theory back then has now become an established paradigm. Other Antibody Drug Conjugates will likely follow, providing in the coming years an expanding arsenal of targeted chemotherapies to be deployed and tailored based on the expression profile of each tumor.”

Quoting Roberto Carmagnani Pestana’s post:

“With great joy, I receive the news that our article ‘Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies’ published in the CA-A Cancer Jounal for Clinicians (IF 254) American Cancer Society was one of the Top Cited Articles of 2022-2023.

A special pleasure to have worked with the great Paolo Tarantino on this publication, which arose from our interaction on X/Twitter! Here is a link to the article.”

Source: Paolo Tarantino/LinkedIn and Roberto Carmagnani Pestana/LinkedIn